SEC Form 4 · accession 0001140361-16-060935
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph E Tyler
Officer — VP, Manufacturing
Period of report
Apr 12, 2016
Accepted (ET)
Apr 12, 2016 · 5:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 12, 2016 | C | 31,260 | $0.00 | A | 42,428 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Preferred StockF1 | $0.00 | Apr 12, 2016 | C | 22,857 | D | — | — | Common Stock | 22,857 | 0 | D |
| Series B Preferred StockF1 | $0.00 | Apr 12, 2016 | C | 8,403 | D | — | — | Common Stock | 8,403 | 0 | D |
Explanation of responses
- F1In connection with the consummation of the Issuer's initial public offering on April 12, 2016, each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of Common Stock for no additional consideration, and had no expiration date. All shares of Common Stock issued upon conversion were aggregated.